Get the Stockscreener App
4.98
3.68%
-0.19
After Hours:
4.98
Immuneering Corp stock is traded at $4.98, with a volume of 943.01K.
It is down -3.68% in the last 24 hours and up +10.18% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$5.17
Open:
$5.1
24h Volume:
943.01K
Relative Volume:
0.58
Market Cap:
$321.56M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-2.6349
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
-0.20%
1M Performance:
+10.18%
6M Performance:
-9.62%
1Y Performance:
+232.00%
1-Day Range:
$4.88
$5.12
1-Week Range:
$4.8363
$5.21
52-Week Range:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.98 | 333.83M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Immuneering to Present at the Leerink Global Healthcare Conference - The Manila Times
IMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 - Yahoo Finance
IMRX Should I Buy - Intellectia AI
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Merger Talk: Does Immuneering Corporation outperform in volatile marketsJuly 2025 Market Mood & Reliable Volume Spike Alerts - baoquankhu1.vn
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Immuneering Corporation to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX - MarketBeat
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What is Immuneering Corporation’s valuation compared to sector2025 Performance Recap & Long-Term Safe Investment Plans - mfd.ru
Empery Asset Management, LP Reduces Stake in Immuneering Corp - GuruFocus
Thomas Schall Buys 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock - Defense World
Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares of Stock - MarketBeat
Immuneering’s (IMRX) chief business officer buys $24,990 in stock By Investing.com - Investing.com Australia
Immuneering’s (IMRX) chief business officer buys $24,990 in stock - Investing.com
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 21,645 Shares of Stock - MarketBeat
Immuneering director Schall buys $101k in shares By Investing.com - Investing.com India
Immuneering director Schall buys $101k in shares - Investing.com
Immuneering Corporation (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest - MarketBeat
Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus
Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Michael Burry, Warren Buffett, Aurelius Capital Management, Balyasny Asset Management, Jain Global, Saba Capital Management, Bain Capital, Immuneering Corp (IMRX), Cloudflare Inc (NET) - Insider Monkey
Director of Immuneering Picks Up 1.8% More Stock - Yahoo Finance
Insider Buying: Leah Neufeld Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus
Immuneering chief people officer Neufeld buys $10,905 in IMRX By Investing.com - Investing.com Nigeria
Immuneering chief people officer Neufeld buys $10,905 in IMRX - Investing.com
Looking Into Immuneering Corp's Recent Short Interest - Sahm
Immuneering director Feinberg buys $86k in shares By Investing.com - Investing.com Nigeria
Immuneering director Feinberg buys $86k in shares - Investing.com
Iridian Asset Management LLC CT Makes New $1.93 Million Investment in Immuneering Corporation $IMRX - MarketBeat
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition - Yahoo Finance
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next - Yahoo Finance
Assessing Immuneering (IMRX) Valuation After Positive Phase 2a Pancreatic Cancer Trial Progress - simplywall.st
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Sahm
Risk Hedge: Can Immuneering Corporation stock deliver strong Q4 earningsJuly 2025 Big Picture & Safe Capital Allocation Plans - ulpravda.ru
Can Immuneering Corporation stock outperform in 2025 bull marketJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - ulpravda.ru
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX) - Seeking Alpha
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink - TipRanks
Stock market today: S&P 500, Dow Jones futures decline — AZZ, Northrop Grumman, Immuneering in focus - MSN
Is Immuneering Corporation stock gaining market shareJuly 2025 Fed Impact & Community Trade Idea Sharing Platform - Улправда
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):